ArticleNature genetics2025
The landscape of N
Abstract read
In one paragraph
Article in Nature genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Oligometastatic prostate cancer - bridging the gap between localized and metastatic disease.Nature reviews. Urology · 2026Review
- CRISPR decodes the RNA regulatory network in prostate cancer: A review from mechanisms to precision therapeutics.Non-coding RNA research · 2026Review
- Lactate metabolism and lactylation in cancer: from pathogenesis to therapeutic advances.Signal transduction and targeted therapy · 2026Review
- m6A Modified VCAN Promotes Glomerular Endothelial Cells Injury and Diabetic Nephropathy by SHH Pathway.Applied biochemistry and biotechnology · 2026Article
- Article
- METTL3-based epitranscriptomic editing screening identifies functional mNature cancer · 2026Article
- EZH2 crosstalk with RNA methylation promotes prostate cancer progression through modulation of m6A autoregulation pathway.The Journal of clinical investigation · 2026Article
- Epitranscriptomic control of cancer hallmarks: Functions, mechanisms, and therapeutics of RNA modifications.Cancer cell · 2026Review
- The emerging role of mFrontiers in immunology · 2026Review
- Theranostic Nanoparticles in Prostate Cancer: Disrupting Hypoxia-Induced Glycolysis by Targeting Hypoxia-Inducible Factor-1 Alpha and Downstream Metabolites.Cancer medicine · 2026Review
- RNA modifications in cancer: from biological insights to therapeutic targets.Bioorganic & medicinal chemistry · 2026Review
- The landscape of NNature genetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors.
Xin Xu *Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0003-4670-1243
Helen Zhu *Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Rupert Hugh-White *Department of Urology, University of California, Los Angeles, Los Angeles, CA, USA.
Julie Livingstone *Department of Urology, University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-8424-3768
Stefan EngDepartment of Urology, University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-5245-6507
Nicole ZeltserDepartment of Urology, University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-7246-2771
Yujuan WangPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Kinga PajdzikDepartment of Chemistry, the University of Chicago, Chicago, IL, USA.
Sujun ChenPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-1941-3951
Kathleen E HoulahanDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Wenqin LuoPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Shun LiuDepartment of Chemistry, the University of Chicago, Chicago, IL, USA.
Xi XuPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Minzhi ShengDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-5668-1314
Wang Yuan GuoPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Jaron ArbetDepartment of Urology, University of California, Los Angeles, Los Angeles, CA, USA.
Yuxi SongDepartment of Urology, University of California, Los Angeles, Los Angeles, CA, USA.
Miranda WangPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Yong ZengPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0001-5719-1272
Shiyan WangPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Guanghui ZhuPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0003-1495-4238
Tingxiao GaoPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0001-7047-1180
Wei ChenPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Xinpei CiPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Wenjie XuMOE Key Laboratory of Metabolism and Molecular Medicine and Department of Biochemistry and Molecular Biology of School of Basic Medical Sciences and Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.ORCID http://orcid.org/0009-0005-4244-2733
Kexin XuDepartment of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.ORCID http://orcid.org/0000-0002-2850-2083
Michele OrainResearch Centre of CHU de Québec-Université Laval, Québec City, Quebec, Canada.
Valerie PicardResearch Centre of CHU de Québec-Université Laval, Québec City, Quebec, Canada.ORCID http://orcid.org/0000-0002-8414-863X
Helene HovingtonResearch Centre of CHU de Québec-Université Laval, Québec City, Quebec, Canada.
Alain BergeronResearch Centre of CHU de Québec-Université Laval, Québec City, Quebec, Canada.ORCID http://orcid.org/0000-0002-2875-0773
Louis LacombeResearch Centre of CHU de Québec-Université Laval, Québec City, Quebec, Canada.ORCID http://orcid.org/0000-0003-4811-0308
Bernard TêtuResearch Centre of CHU de Québec-Université Laval, Québec City, Quebec, Canada.
Yves FradetResearch Centre of CHU de Québec-Université Laval, Québec City, Quebec, Canada.
Mathieu LupienPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Gong-Hong WeiMOE Key Laboratory of Metabolism and Molecular Medicine and Department of Biochemistry and Molecular Biology of School of Basic Medical Sciences and Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0001-6546-9334
Marianne KoritzinskyPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Robert G BristowDivision of Cancer Sciences, University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-8553-9544
Neil E FleshnerPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Xue WuGeneseeq Research Institute, Geneseeq Technology lnc., Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-5567-1325
Yang ShaoGeneseeq Research Institute, Geneseeq Technology lnc., Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0003-4585-1792
Chuan HeDepartment of Chemistry, the University of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0003-4319-7424
Alejandro BerlinPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-1880-6905
Theodorus van der KwastPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0001-8640-5786
Hon LeongDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Paul C BoutrosDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. pboutros@mednet.ucla.edu.ORCID http://orcid.org/0000-0003-0553-7520
Housheng Hansen HePrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada. hansenhe@uhnresearch.ca.ORCID http://orcid.org/0000-0003-2898-3363
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5MTraining Grant in Genomic Analysis and InterpretationT32HG002536 · NHGRI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Valerie A Arboleda, Harold Pimentel · 2002 to 2026
$8.6MAdvancing method benchmarking and data sharing through crowd-sourced competitions in cancer researchU24CA248265 · NCI · SAGE BIONETWORKS · PI BOUTROS, PAUL CHRISTOPHER, VARMA, SUSHEEL · 2020 to 2024
$4.1MRandomized Trial of Exercise Therapy on Markers of Progression in Localized Prostate Cancer:R01CA272678 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Paul Christopher Boutros, LEE W JONES · 2022 to 2026
$3.6MVirginia-UCLA-Toronto Biomarker Characterization CenterU2CCA271894 · NCI · OLD DOMINION UNIVERSITY · PI OLIVER John SEMMES · 2022 to 2026
$3.2MDevelopment of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate CancerU01CA214194 · NCI · EASTERN VIRGINIA MEDICAL SCHOOL · PI BOUTROS, PAUL CHRISTOPHER, KISLINGER, THOMAS · 2016 to 2021
$2.5MPredicting prostate cancer clinical outcomes with germline genomic biomarkersF31CA281168 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZELTSER, NICOLE · 2024 to 2025
$83kGouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre) 142246, 152863, 152864 and 159567NCI NIH HHS F31 CA281168NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA272678NCI NIH HHS U01 CA214194NCI NIH HHS U24 CA248265NCI NIH HHS U2C CA271894NHGRI NIH HHS T32 HG002536
Abstract
N
Indexed as
AdenosineProstatic NeoplasmsBiomarkers, TumorGene Expression Regulation, NeoplasticHumansMaleMutationPrognosisTranscriptomeAdenosineBiomarkers, TumorN-methyladenosine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.